Arginine/lysine: Difference between revisions
Entranced98 (talk | contribs) Importing Wikidata short description: "Combination drug" |
update infobox, links, templates |
||
Line 1: | Line 1: | ||
{{Short description|Combination drug}} |
{{Short description|Combination drug}} |
||
{{One source|date=July 2020}} |
|||
{{Use American English|date=July 2020}} |
{{Use American English|date=July 2020}} |
||
{{Use dmy dates|date=July 2020}} |
{{Use dmy dates|date=July 2020}} |
||
{{cs1 config |name-list-style=vanc |display-authors=6}} |
|||
{{Infobox drug |
{{Infobox drug |
||
| drug_name = |
|||
| type = combo |
| type = combo |
||
| image = |
| image = |
||
Line 17: | Line 15: | ||
<!-- Combo data --> |
<!-- Combo data --> |
||
| component1 = Arginine |
| component1 = Arginine |
||
| class1 = Amino acid |
| class1 = [[Amino acid]] |
||
| component2 = Lysine |
| component2 = Lysine |
||
| class2 = Amino acid |
| class2 = [[Amino acid]] |
||
<!-- Clinical data --> |
<!-- Clinical data --> |
||
| pronounce = |
| pronounce = |
||
| tradename = |
| tradename = Lysakare |
||
| Drugs.com = |
| Drugs.com = |
||
| MedlinePlus = |
| MedlinePlus = |
||
| licence_CA = <!-- Health Canada may use generic or brand name (generic name preferred) --> |
|||
| licence_EU = yes |
|||
| DailyMedID = |
| DailyMedID = |
||
| licence_US = <!-- FDA may use generic or brand name (generic name preferred) --> |
|||
| pregnancy_ |
| pregnancy_ |
||
| pregnancy_ |
| pregnancy_ |
||
| pregnancy_US = <!-- A / B / C / D / X / N --> |
|||
| pregnancy_US_comment = |
|||
| pregnancy_category= |
| pregnancy_category= |
||
⚫ | |||
| dependency_liability = |
|||
| addiction_liability = |
|||
⚫ | |||
| ATCvet = |
|||
| ATC_prefix = V03 |
| ATC_prefix = V03 |
||
| ATC_suffix = AF11 |
| ATC_suffix = AF11 |
||
Line 54: | Line 44: | ||
| legal_NZ = <!-- Class A, B, C --> |
| legal_NZ = <!-- Class A, B, C --> |
||
| legal_NZ_comment = |
| legal_NZ_comment = |
||
| legal_UK = POM |
|||
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C --> |
|||
| legal_UK_comment = <ref>{{cite web | title=Lysakare Summary of Product Characteristics (SmPC) | website=(emc) | date=2 May 2024 | url=https://www.medicines.org.uk/emc/product/12724/smpc | access-date=24 May 2024}}</ref> |
|||
| legal_UK_comment = |
|||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
||
| legal_US_comment = |
| legal_US_comment = |
||
| legal_EU = Rx-only |
| legal_EU = Rx-only |
||
| legal_EU_comment = |
| legal_EU_comment = <ref name="LysaKare EPAR" /> |
||
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> |
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV --> |
||
| legal_UN_comment = |
| legal_UN_comment = |
||
Line 65: | Line 55: | ||
<!-- Identifiers --> |
<!-- Identifiers --> |
||
| CAS_number_Ref = |
|||
| CAS_number = 2447636-40-8 |
| CAS_number = 2447636-40-8 |
||
| PubChem = |
| PubChem = |
||
| IUPHAR_ligand = |
| IUPHAR_ligand = |
||
| DrugBank_Ref = |
|||
| DrugBank = |
| DrugBank = |
||
| ChemSpiderID_Ref = |
|||
| ChemSpiderID = |
| ChemSpiderID = |
||
| UNII_Ref = |
|||
| UNII = |
| UNII = |
||
| KEGG_Ref = |
|||
| KEGG = D12136 |
| KEGG = D12136 |
||
| ChEBI_Ref = |
|||
| ChEBI = |
| ChEBI = |
||
| ChEMBL_Ref = |
|||
| ChEMBL = |
| ChEMBL = |
||
| NIAID_ChemDB = |
| NIAID_ChemDB = |
||
Line 86: | Line 70: | ||
}} |
}} |
||
'''Arginine/lysine''', sold under the brand name ''' |
'''Arginine/lysine''', sold under the brand name '''Lysakare''', is a fixed-dose [[combination medication]] used to protect the kidneys from radiation damage during cancer treatment with a radioactive medicine called [[DOTA-TATE#Lutetium Lu 177|lutetium (<sup>177</sup>Lu) oxodotreotide]].<ref name="LysaKare EPAR">{{cite web | title=Lysakare EPAR | website=[[European Medicines Agency]] (EMA) | date=24 May 2019 | url=https://www.ema.europa.eu/en/medicines/human/EPAR/lysakare | access-date=22 July 2020}} Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.</ref> It contains <small>L</small>-[[arginine]] hydrochloride and <small>L</small>-[[lysine]] hydrochloride.<ref name="LysaKare EPAR" /> |
||
The most common side effects include nausea and vomiting.<ref name="LysaKare EPAR" /> Arginine/lysine is also associated with hyperkalaemia (high blood potassium levels), but the frequency of this side effect is not known.<ref name="LysaKare EPAR" /> Side effects with arginine/lysine are usually mild or moderate.<ref name="LysaKare EPAR" /> |
The most common side effects include nausea and vomiting.<ref name="LysaKare EPAR" /> Arginine/lysine is also associated with hyperkalaemia (high blood potassium levels), but the frequency of this side effect is not known.<ref name="LysaKare EPAR" /> Side effects with arginine/lysine are usually mild or moderate.<ref name="LysaKare EPAR" /> |
||
Line 95: | Line 79: | ||
== Medical uses == |
== Medical uses == |
||
Arginine/lysine is indicated for reduction of renal radiation exposure during [[peptide receptor radionuclide therapy]] (PRRT) with lutetium (<sup>177</sup>Lu) oxodotreotide in adults.<ref name="LysaKare EPAR" /> |
Arginine/lysine is [[indicated]] for reduction of renal radiation exposure during [[peptide receptor radionuclide therapy]] (PRRT) with lutetium (<sup>177</sup>Lu) oxodotreotide in adults.<ref name="LysaKare EPAR" /> |
||
== References == |
== References == |
||
{{Reflist}} |
{{Reflist}} |
||
{{Detoxifying agents for antineoplastic treatment}} |
|||
== External links == |
|||
⚫ | |||
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/rn/74-79-3 | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Arginine }} |
|||
{{Authority control}} |
|||
* {{cite web | url = https://druginfo.nlm.nih.gov/drugportal/name/lysine | publisher = U.S. National Library of Medicine | work = Drug Information Portal | title = Lysine }} |
|||
⚫ | |||
{{DEFAULTSORT:Arginine Lysine}} |
{{DEFAULTSORT:Arginine Lysine}} |
Revision as of 06:29, 24 May 2024
Combination of | |
---|---|
Arginine | Amino acid |
Lysine | Amino acid |
Clinical data | |
Trade names | Lysakare |
Routes of administration | Intravenous infusion |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Arginine/lysine, sold under the brand name Lysakare, is a fixed-dose combination medication used to protect the kidneys from radiation damage during cancer treatment with a radioactive medicine called lutetium (177Lu) oxodotreotide.[2] It contains L-arginine hydrochloride and L-lysine hydrochloride.[2]
The most common side effects include nausea and vomiting.[2] Arginine/lysine is also associated with hyperkalaemia (high blood potassium levels), but the frequency of this side effect is not known.[2] Side effects with arginine/lysine are usually mild or moderate.[2]
Radiation from lutetium (177Lu) oxodotreotide can cause damage when the medicine passes through tubules in the kidney.[2] Arginine and lysine interfere with the passage of lutetium (177Lu) oxodotreotide through these kidney tubules.[2] As a result, the radioactive medicine leaves the body in the urine and the kidneys are exposed to less radiation.[2]
Arginine/lysine was approved for medical use in the European Union in July 2019.[2]
Medical uses
Arginine/lysine is indicated for reduction of renal radiation exposure during peptide receptor radionuclide therapy (PRRT) with lutetium (177Lu) oxodotreotide in adults.[2]
References
- ^ "Lysakare Summary of Product Characteristics (SmPC)". (emc). 2 May 2024. Retrieved 24 May 2024.
- ^ a b c d e f g h i j k "Lysakare EPAR". European Medicines Agency (EMA). 24 May 2019. Retrieved 22 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.